Scienture Holdings, Inc.
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
SCNX$3.04-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. CONSOLIDATED STATEMENTS OF CASH FLOWS
Years Ended December 31, 2024 and 2023
| Year Ended | ||||
|---|---|---|---|---|
| December 31, | ||||
| 2024 · 2023 | ||||
| Cash flows from operating activities: | ||||
| Net loss from continuing operations | $(18,778,876) | $(8,482,864) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation expense | 2,000 | 19,375 | ||
| Change in fair value of warrant liability | 182,982 | 148,420 | ||
| Change in fair value of derivative liability | (180,383) | - | ||
| Options expense | 25,584 | 29,738 | ||
| Common stock issued for services | 4,598,294 | 257,772 | ||
| Impairment of investment | 2,500,000 | - | ||
| Amortization of debt discount | 912,447 | - | ||
| Amortization of right-of-use assets | 51,361 | 215,665 | ||
| Amortization of intangible assets | - | 814,790 | ||
| Goodwill impairment | - | 5,129,115 | ||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable, net | (11,106) | (293,784) | ||
| Prepaid expenses and deposits | 34,656 | 38,367 | ||
| Inventory | 968 | 4,232,947 | ||
| Other receivables | (2,914,068) | (254,924) | ||
| Lease liability | (51,587) | (228,470) | ||
| Accounts payable | 448,572 | 1,607,625 | ||
| Accrued liabilities | (44,616) | 58,692 | ||
| Purchase price payable | - | 350,000 | ||
| Current liabilities | (62,390) | 2,794 | ||
| Net cash (used in) provided by operating activities from continuing operations | (13,286,163) | 3,645,257 | ||
| Net cash used in operating activities from discontinued operations | (979,075) | (5,870,449) | ||
| Net cash used in operating activities | (14,265,239) | (2,225,192) | ||
| Cash flows from investing activities: | ||||
| Cash received in acquisition | 132,976 | - | ||
| Acquisition of property and equipment | (12,000) | - | ||
| Investment in securities | (2,500,000) | - | ||
| Funds acquired through acquisitions | - | (344,454) | ||
| Net cash used in investing activities from continuing operations | (2,379,024) | (344,454) | ||
| Net cash provided by investing activities from discontinued operations | 29,931,815 | 68,737 | ||
| Net cash provided by (used in) investing activities | 27,552,791 | (275,717) | ||
| Cash flows from financing activities: | ||||
| Repayment of contingent liability | (1,246,346) | (1,043,107) | ||
| Proceeds from issuance from debt | - | 400,000 | ||
| Repayment of debt | - | (150,000) | ||
| Proceeds from loan payable, related party | 150,000 | - | ||
| Proceeds from issuance of convertible notes, net of issuance costs | 2,954,000 | - | ||
| Cash dividends paid | (14,858,831) | - | ||
| Proceeds from sale of future revenue | - | 2,181,417 | ||
| Proceeds from exercise of warrants | 16,567 | 1,622 | ||
| Proceeds from securities purchase agreement | - | 516,400 | ||
| Proceeds from exercise of options | 9,840 | - | ||
| Net cash (used in) provided by financing activities from continuing operations | (12,974,770) | 1,906,332 | ||
| Net cash used in financing activities from discontinued operations | (5,000) | (500,000) | ||
| Net cash (used in) provided by financing activities | (12,979,770) | 1,406,332 | ||
| Net change in cash | 307,782 | (1,094,577) | ||
| Cash at beginning of year | 314 | 1,094,891 | ||
| Cash at end of year | $308,096 | $314 | ||
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for interest | $ | - | $733,694 | |
| Cash paid for taxes | $ | - | $ | - |
| Supplemental disclosure of non-cash investing and financing activities: | ||||
| Issuance of shares pursuant to Merger | $78,646,184 | $ | - | |
| Assets acquired in connection with Merger | $194,554 | $ | - | |
| Liabilities assumed in connection with Merger | $5,797,117 | $ | - | |
| Insurance premium financed | $198,245 | $306,152 | ||
| Warrants issued with convertible note | $71,332 | $ | - | |
| Issuance of common shares in connection with converible debenture | $420,200 | $ | - | |
| Equity line of commitment shares issued as offering costs | $534,800 | $ | - | |
| Derivative liability recognized in connection with issuance of convertible note | $2,477,217 | $ | - | |
| Note issued as SOSRx contribution | $ | - | $500,000 | |
| Disposition of assets, related party | $ | - | $492,030 | |
| Issuance of note receivable | $ | - | $1,300,000 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.